Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Monthly Macro with Richard de Chazal: Economic Outlook 2025

    William Blair macro analyst Richard de Chazal looks back at the economic highlights of 2024 and shares his insights and predictions for the U.S. economy in 2025, emphasizing resilience, consumer strength, and potential risks ahead.

    Listen to the podcast

  • U.S. Exceptionalism Continues Through 2025

    As “the year of testing resiliency” comes to a close, many may wonder what to expect in 2025. Macro Analyst Richard de Chazal explores consumer spending, inflation, the strength of the U.S. dollar, and more, in his latest Economics Outlook.

    Read more

  • Emerging Markets 2025: A Landscape of Opportunity

    Learn why our global equity and emerging markets debt teams believe emerging markets remain an efficient gateway to powerful secular themes in 2025.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures